medwireNews: ESMO has released an updated version of its Clinical Practice Guideline for the management of immunotherapy-related toxicities in people with cancer.
The document is published in the Annals of Oncology and supersedes the previous version from 2017.
The authors – a multidisciplinary group of experts from Europe, Australia, and the USA – address the diagnosis, treatment, and follow-up of the most common immunotherapy-related adverse events, including cardiovascular, dermatologic, gastrointestinal, neurologic, and pulmonary toxicities as well as endocrinopathies. They provide guidance on assessment and treatment algorithms according to the grade of toxicity.
The “[r]ecommendations are based on available scientific data and [our] collective expert opinion,” note the guideline authors, adding that they followed the ESMO standard operating procedures for Clinical Practice Guideline development.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group